Observational studyPM & R : the journal of injury, function, and rehabilitation2026
Relief of pain associated with spasticity in adult patients after treatment with onabotulinumtoxinA: Post hoc observational results from the ASPIRE study.
Observational study in PM & R : the journal of injury, function, and rehabilitation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01930786 (ASPIRE), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPain is often observed in patients with spasticity, but little is known about the relationship between pain and spasticity and the effectiveness of treating pain with botulinum toxins in these patients.
objectiveTo explore onabotulinumtoxinA (onabotA) use and pain relief in patients with spasticity with pain at baseline.
designSubanalysis of a 2-year multicenter, prospective, observational study (ASPIRE [Adult Spasticity International Registry], NCT01930786).
settingFifty-four international clinical sites.
participantsAdults with spasticity (N = 494) and pain at baseline (Numeric Pain Rating Scale [NPRS]>0) across multiple etiologies and age groups.
interventionOnabotA administered at clinician's discretion. MAIN OUTCOMES: OnabotA use, pain measured with the NPRS and Disability Assessment Scale (DAS), patient- and physician-reported satisfaction, and safety.
resultsOf 730 patients who received ≥1 onabotA dose in ASPIRE, 494 (68%) had baseline pain (mean age, 54 years; stroke, 56%; naïve to onabotA, 38%; NPRS ≥5, 65%). Average onabotA dose per treatment session (Tx) ranged from 345 to 463 U. Pain reduction from baseline was observed across all Tx; mean NPRS decreased from 5.4 to 2.6 at Tx8, model estimated mean NPRS was significantly reduced after each Tx (Tx1-7, p ≤ .001; Tx8, p ≤ .005), and a high proportion achieved clinically meaningful pain reductions across Tx1-4 (mean NPRS decreased by ≥30% for 49%-59%, by ≥50% for 40%-49%, and by ≥70% for 24%-34% of patients). Relief of pain was supported by significant improvements from baseline on the DAS pain subscale across most Tx with most patients/physicians being satisfied with onabotA treatment. Overall, 15 patients (3%) reported 17 treatment-related adverse events (TRAEs), and 2 patients (0.4%) reported 3 serious TRAEs.
conclusionIn patients with spasticity experiencing pain, long-term onabotA treatment demonstrated consistent clinically meaningful reductions in pain, reduced pain disability on DAS, and high patient and physician satisfaction with no new safety signals identified, regardless of prior onabotA treatment or age groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.